Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gout Prophylaxis and Disease Burden

J Rheumatol; ePub 2016 Mar 15; Schlesinger, Etzel, et al

Publish date:: March 28, 2016

Gout prophylaxis was significantly more common in patients with a higher disease burden and activity, which is in agreement with the American College of Rheumatology guidelines, according to a study of 1,049 patients with gout, including 42% receiving prophylaxis and 58% not receiving prophylaxis. Researchers found:

• Drugs most commonly used for prophylaxis were colchicine (78%), and nonsteroidal anti-inflammatory drugs (32%).

• Prophylaxis drug combination was used by 10.2% of patients.

• Patients receiving prophylaxis were more likely to have a gout duration of ≤1 year, ≥1 flare in the year prior to enrollment, ≥1 healthcare uses in the last year, have tophi, report pain, and have disease activity >10 vs patients not receiving prophylaxis.

Citation: Schlesinger N, Etzel CJ, Greenberg J, Kremer J, and Harrold LR. Gout prophylaxis evaluated according to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. [Published online ahead of print March 15, 2016]. J Rheumatol. doi:10.3899/jrheum.150345.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Gout

Weight loss may be paramount lifestyle change in preventing gout,

FAST trial clears febuxostat of increased mortality in gout,

RECIPE trial cooks up gout therapy improvement,

Decline in febuxostat use trends with cardiovascular concerns,

DECT has mixed performance in differentiating gout vs. CPPD,